The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | Current and potential PI3K and BTK inhibitors for CLL
Jennifer Woyach, MD of The Ohio State University Comprehensive Cancer Center, Columbus, OH gives an overview of her talk on new compounds for chronic lymphocytic leukaemia (CLL) held at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Dr Woyach discusses the new PI3K and BTK inhibitors and the new targeted therapies, such as antibodies. With the PI3K and BTK inhibitors, the focus has been on trying to improve efficacy and minimizing toxicity. She further discusses the PI3K inhibitors duvelisib and TGR-1202. In terms of BTK inhibitors, acalabrutinib as well as GDC-0853, SNS-062 and ARQ 531.
